Research on Neoadjuvant Therapy for Gastric Cancer
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Gastrointestinal Oncology".
Deadline for manuscript submissions: closed (31 May 2025) | Viewed by 1142
Special Issue Editor
Special Issue Information
Dear Colleagues,
Gastric cancer continues to pose a major health challenge worldwide, with high incidence and mortality rates. The treatment landscape has evolved significantly with the introduction of neoadjuvant therapy, which involves administering therapeutic interventions before surgery to improve outcomes. This Special Issue, "Research on Neoadjuvant Therapy for Gastric Cancer", provides a comprehensive overview of the current state and advancements in this critical area. Combination of surgery and chemotherapy, radiotherapy, and immunotherapy increases treatment effectiveness through sterilization of cancer microfoci not covered by surgical treatment by lowering the risk of locoregional relapse and/or distant metastases, and as a consequence, improvement of long-term results. Furthermore, the primary tumor regression can increase the overall rate of resectability and complete surgery. This issue features cutting-edge research on novel drug regimens, biomarkers for treatment response, and strategies for personalized therapy. We hope this compilation serves as a valuable resource for researchers, clinicians, and policymakers dedicated to advancing gastric cancer treatment and improving patient outcomes.
Prof. Dr. Jerzy Wydmanski
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- gastric cancer
- neoadjuvant therapy
- preoperative treatment
- radiotherapy
- chemotherapy
- targeted therapy
- immunotherapy
- tumor resectability
- treatment response biomarkers
- personalized therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
